English

SGX PHARMACEUTICALS, INC.

EDGAR

Quarterly report (10-Q) · filed 2008-08-07

11 filing records in this dataset, filed from 2006-03-31 to 2008-08-07. Explore the available filing history and original sources.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

4.31 million USD

2008-06-30 · USD

Exact inputs and evidence

Revenue: 4306000 USD Source

Operating margin

-167.07%

2008-06-30 · %

Exact inputs and evidence

Operating Income: -7194000 USD Source
Revenue: 4306000 USD Source

Operating cash flow

-6.38 million USD

2008-06-30 · USD

Exact inputs and evidence

Operating Cash Flow: -13240000 USD Source
Operating Cash Flow: -6862000 USD Source

Free cash flow

-6.38 million USD

2008-06-30 · USD

Exact inputs and evidence

Operating Cash Flow: -13240000 USD Source
Operating Cash Flow: -6862000 USD Source
Capital Expenditure: 348000 USD Source
Capital Expenditure: 343000 USD Source

Cash and cash equivalents: 22.9 million USD 2008-06-30 Source
Exact value

22870000 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

36.5 million USD

2007-07-01 – 2008-06-30

Exact inputs and evidence

Revenue: 7586000 USD · 2007-07-01 – 2007-09-30 Source
Revenue: 34739000 USD · 2007-01-01 – 2007-12-31 Source
Revenue: 27060000 USD · 2007-01-01 – 2007-09-30 Source
Revenue: 16972000 USD · 2008-01-01 – 2008-03-31 Source
Revenue: 4306000 USD · 2008-04-01 – 2008-06-30 Source

Net income

-14.4 million USD

2007-07-01 – 2008-06-30

Exact inputs and evidence

Net income: -4773000 USD · 2007-07-01 – 2007-09-30 Source
Net income: -16007000 USD · 2007-01-01 – 2007-12-31 Source
Net income: -9884000 USD · 2007-01-01 – 2007-09-30 Source
Net income: 3721000 USD · 2008-01-01 – 2008-03-31 Source
Net income: -7201000 USD · 2008-04-01 – 2008-06-30 Source

Operating cash flow

-23.3 million USD

2007-07-01 – 2008-06-30

Exact inputs and evidence

Operating cash flow: -9904000 USD · 2007-01-01 – 2007-09-30 Source
Operating cash flow: -4185000 USD · 2007-01-01 – 2007-06-30 Source
Operating cash flow: -14252000 USD · 2007-01-01 – 2007-12-31 Source
Operating cash flow: -9904000 USD · 2007-01-01 – 2007-09-30 Source
Operating cash flow: -6862000 USD · 2008-01-01 – 2008-03-31 Source
Operating cash flow: -13240000 USD · 2008-01-01 – 2008-06-30 Source
Operating cash flow: -6862000 USD · 2008-01-01 – 2008-03-31 Source

Capital expenditure

631 thousand USD

2007-07-01 – 2008-06-30

Exact inputs and evidence

Capital expenditure: 242000 USD · 2007-01-01 – 2007-09-30 Source
Capital expenditure: 83000 USD · 2007-01-01 – 2007-06-30 Source
Capital expenditure: 366000 USD · 2007-01-01 – 2007-12-31 Source
Capital expenditure: 242000 USD · 2007-01-01 – 2007-09-30 Source
Capital expenditure: 343000 USD · 2008-01-01 – 2008-03-31 Source
Capital expenditure: 348000 USD · 2008-01-01 – 2008-06-30 Source
Capital expenditure: 343000 USD · 2008-01-01 – 2008-03-31 Source

Free cash flow

-23.9 million USD

2007-07-01 – 2008-06-30

Exact inputs and evidence

Operating cash flow: -9904000 USD · 2007-01-01 – 2007-09-30 Source
Operating cash flow: -4185000 USD · 2007-01-01 – 2007-06-30 Source
Operating cash flow: -14252000 USD · 2007-01-01 – 2007-12-31 Source
Operating cash flow: -9904000 USD · 2007-01-01 – 2007-09-30 Source
Operating cash flow: -6862000 USD · 2008-01-01 – 2008-03-31 Source
Operating cash flow: -13240000 USD · 2008-01-01 – 2008-06-30 Source
Operating cash flow: -6862000 USD · 2008-01-01 – 2008-03-31 Source
Capital expenditure: 242000 USD · 2007-01-01 – 2007-09-30 Source
Capital expenditure: 83000 USD · 2007-01-01 – 2007-06-30 Source
Capital expenditure: 366000 USD · 2007-01-01 – 2007-12-31 Source
Capital expenditure: 242000 USD · 2007-01-01 – 2007-09-30 Source
Capital expenditure: 343000 USD · 2008-01-01 – 2008-03-31 Source
Capital expenditure: 348000 USD · 2008-01-01 – 2008-06-30 Source
Capital expenditure: 343000 USD · 2008-01-01 – 2008-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2008-08-07.

Financial data available through: 2007-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2007-12-31
Operating income: 5 of 11 periods available· newest 2007-12-31
Net income: 5 of 11 periods available· newest 2007-12-31
Operating cash flow: 5 of 11 periods available· newest 2007-12-31
Capital expenditure: 5 of 11 periods available· newest 2007-12-31
Total assets: 4 of 11 periods available· newest 2007-12-31
liabilities: No compatible figures in this window
Current assets: 4 of 11 periods available· newest 2007-12-31
Current liabilities: 4 of 11 periods available· newest 2007-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2007-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+25.1%

Prior period

USD 27.78 million

2006-01-01 – 2006-12-31
Current period

USD 34.74 million

2007-01-01 – 2007-12-31

Exact inputs and evidence

34739000 − 27780000 = 6959000 USD

27780000 USD · 2006-01-01 – 2006-12-31
Inspect prior input Prior source
34739000 USD · 2007-01-01 – 2007-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · SGX PHARMACEUTICALS, INC. · 2007-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Year-over-year change in Revenue: 6959000 USD Concept: fundies:Revenue Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 34739000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#14922 Input fundies:Revenue: 27780000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#14922
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 12.05 million

Prior period

−USD 28.05 million

2006-01-01 – 2006-12-31
Current period

−USD 16.01 million

2007-01-01 – 2007-12-31

Exact inputs and evidence

-16007000 − -28052000 = 12045000 USD

-28052000 USD · 2006-01-01 – 2006-12-31
Inspect prior input Prior source
-16007000 USD · 2007-01-01 – 2007-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · SGX PHARMACEUTICALS, INC. · 2007-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Year-over-year change in Net income: 12045000 USD Concept: fundies:NetIncome Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -16007000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21038 Input fundies:NetIncome: -28052000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21038
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 8.36 million

Prior period

−USD 5.89 million

2006-01-01 – 2006-12-31
Current period

−USD 14.25 million

2007-01-01 – 2007-12-31

Exact inputs and evidence

-14252000 − -5891000 = -8361000 USD

-5891000 USD · 2006-01-01 – 2006-12-31
Inspect prior input Prior source
-14252000 USD · 2007-01-01 – 2007-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · SGX PHARMACEUTICALS, INC. · 2007-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Year-over-year change in Operating cash flow: -8361000 USD Concept: fundies:OperatingCashFlow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -14252000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21809 Input fundies:OperatingCashFlow: -5891000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21809
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-75.3%

Prior period

USD 1.48 million

2006-01-01 – 2006-12-31
Current period

USD 366,000

2007-01-01 – 2007-12-31

Exact inputs and evidence

366000 − 1483000 = -1117000 USD

1483000 USD · 2006-01-01 – 2006-12-31
Inspect prior input Prior source
366000 USD · 2007-01-01 – 2007-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · SGX PHARMACEUTICALS, INC. · 2007-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Year-over-year change in Capital expenditure: -1117000 USD Concept: fundies:CapitalExpenditure Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 366000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21981 Input fundies:CapitalExpenditure: 1483000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21981
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2007 2007-01-01 – 2007-12-31

Revenue USD 34.74 million 100% of revenue
Operating costs Derived USD 50.89 million 146% of revenue
Operating income −USD 16.15 million −46% of revenue
Tax, interest and other Derived −USD 145,000 −0.4% of revenue
Net income −USD 16.01 million −46% of revenue

Cash

Operating cash flow −USD 14.25 million −41% of revenue
Capital expenditure USD 366,000 1.1% of revenue
Free cash flow Derived −USD 14.62 million −42% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2003 Operating loss: operating costs were 199% of revenue.
2004 Operating loss: operating costs were 154% of revenue.
2005 Operating loss: operating costs were 230% of revenue.
2006 Operating loss: operating costs were 203% of revenue.
2007 Operating loss: operating costs were 146% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2003 2003-01-01 – 2003-12-31	18078000	35940000 Derived	-17862000	899000 Derived	-18761000	-7625000 Derived	Source 2003-01-01 – 2003-12-31: 18078000 USD Inspect Revenue Open source 2003-01-01 – 2003-12-31: -17862000 USD Inspect Operating Income Open source 2003-01-01 – 2003-12-31: -18761000 USD Inspect Net Income Open source 2003-01-01 – 2003-12-31: -6312000 USD Inspect Operating Cash Flow Open source 2003-01-01 – 2003-12-31: 1313000 USD Inspect Capital Expenditure Open source
2004 2004-01-01 – 2004-12-31	27297000	42163000 Derived	-14866000	3886000 Derived	-18752000	-12159000 Derived	Source 2004-01-01 – 2004-12-31: 27297000 USD Inspect Revenue Open source 2004-01-01 – 2004-12-31: -14866000 USD Inspect Operating Income Open source 2004-01-01 – 2004-12-31: -18752000 USD Inspect Net Income Open source 2004-01-01 – 2004-12-31: -10984000 USD Inspect Operating Cash Flow Open source 2004-01-01 – 2004-12-31: 1175000 USD Inspect Capital Expenditure Open source
2005 2005-01-01 – 2005-12-31	21636000	49701000 Derived	-28065000	1326000 Derived	-29391000	-13145000 Derived	Source 2005-01-01 – 2005-12-31: 21636000 USD Inspect Revenue Open source 2005-01-01 – 2005-12-31: -28065000 USD Inspect Operating Income Open source 2005-01-01 – 2005-12-31: -29391000 USD Inspect Net Income Open source 2005-01-01 – 2005-12-31: -11842000 USD Inspect Operating Cash Flow Open source 2005-01-01 – 2005-12-31: 1303000 USD Inspect Capital Expenditure Open source
2006 2006-01-01 – 2006-12-31	27780000	56530000 Derived	-28750000	-698000 Derived	-28052000	-7374000 Derived	Source 2006-01-01 – 2006-12-31: 27780000 USD Inspect Revenue Open source 2006-01-01 – 2006-12-31: -28750000 USD Inspect Operating Income Open source 2006-01-01 – 2006-12-31: -28052000 USD Inspect Net Income Open source 2006-01-01 – 2006-12-31: -5891000 USD Inspect Operating Cash Flow Open source 2006-01-01 – 2006-12-31: 1483000 USD Inspect Capital Expenditure Open source
2007 2007-01-01 – 2007-12-31	34739000	50891000 Derived	-16152000	-145000 Derived	-16007000	-14618000 Derived	Source 2007-01-01 – 2007-12-31: 34739000 USD Inspect Revenue Open source 2007-01-01 – 2007-12-31: -16152000 USD Inspect Operating Income Open source 2007-01-01 – 2007-12-31: -16007000 USD Inspect Net Income Open source 2007-01-01 – 2007-12-31: -14252000 USD Inspect Operating Cash Flow Open source 2007-01-01 – 2007-12-31: 366000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 34.7M 2007

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20032003-12-31	Revenue	18078000	Revenue: 18078000 Open source
20042004-12-31	Revenue	27297000	Revenue: 27297000 Open source
20052005-12-31	Revenue	21636000	Revenue: 21636000 Open source
20062006-12-31	Revenue	27780000	Revenue: 27780000 Open source
20072007-12-31	Revenue	34739000	Revenue: 34739000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

25.1% 2007

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20032003-12-31	Year over year	No prior comparable period	Revenue: 18078000 Open source
20042004-12-31	Year over year	51%	Revenue: 27297000 Open source Revenue: 18078000 Open source
20052005-12-31	Year over year	-20.7%	Revenue: 21636000 Open source Revenue: 27297000 Open source
20062006-12-31	Year over year	28.4%	Revenue: 27780000 Open source Revenue: 21636000 Open source
20072007-12-31	Year over year	25.1%	Revenue: 34739000 Open source Revenue: 27780000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -46.5% 2007

Net margin -46.1% 2007

Free cash flow margin -42.1% 2007

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20032003-12-31	Operating margin	-98.8%	Operating Income: -17862000 Open source Revenue: 18078000 Open source
20042004-12-31	Operating margin	-54.5%	Operating Income: -14866000 Open source Revenue: 27297000 Open source
20052005-12-31	Operating margin	-129.7%	Operating Income: -28065000 Open source Revenue: 21636000 Open source
20062006-12-31	Operating margin	-103.5%	Operating Income: -28750000 Open source Revenue: 27780000 Open source
20072007-12-31	Operating margin	-46.5%	Operating Income: -16152000 Open source Revenue: 34739000 Open source
20032003-12-31	Net margin	-103.8%	Net Income: -18761000 Open source Revenue: 18078000 Open source
20042004-12-31	Net margin	-68.7%	Net Income: -18752000 Open source Revenue: 27297000 Open source
20052005-12-31	Net margin	-135.8%	Net Income: -29391000 Open source Revenue: 21636000 Open source
20062006-12-31	Net margin	-101%	Net Income: -28052000 Open source Revenue: 27780000 Open source
20072007-12-31	Net margin	-46.1%	Net Income: -16007000 Open source Revenue: 34739000 Open source
20032003-12-31	Free cash flow margin	-42.2%	Revenue: 18078000 Open source Operating Cash Flow: -6312000 Open source Capital Expenditure: 1313000 Open source
20042004-12-31	Free cash flow margin	-44.5%	Revenue: 27297000 Open source Operating Cash Flow: -10984000 Open source Capital Expenditure: 1175000 Open source
20052005-12-31	Free cash flow margin	-60.8%	Revenue: 21636000 Open source Operating Cash Flow: -11842000 Open source Capital Expenditure: 1303000 Open source
20062006-12-31	Free cash flow margin	-26.5%	Revenue: 27780000 Open source Operating Cash Flow: -5891000 Open source Capital Expenditure: 1483000 Open source
20072007-12-31	Free cash flow margin	-42.1%	Revenue: 34739000 Open source Operating Cash Flow: -14252000 Open source Capital Expenditure: 366000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -14.3M 2007

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20032003-12-31	Operating cash flow	-6312000	Operating Cash Flow: -6312000 Open source
20042004-12-31	Operating cash flow	-10984000	Operating Cash Flow: -10984000 Open source
20052005-12-31	Operating cash flow	-11842000	Operating Cash Flow: -11842000 Open source
20062006-12-31	Operating cash flow	-5891000	Operating Cash Flow: -5891000 Open source
20072007-12-31	Operating cash flow	-14252000	Operating Cash Flow: -14252000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -14.6M 2007

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20032003-12-31	Free cash flow	-7625000	Operating Cash Flow: -6312000 Open source Capital Expenditure: 1313000 Open source
20042004-12-31	Free cash flow	-12159000	Operating Cash Flow: -10984000 Open source Capital Expenditure: 1175000 Open source
20052005-12-31	Free cash flow	-13145000	Operating Cash Flow: -11842000 Open source Capital Expenditure: 1303000 Open source
20062006-12-31	Free cash flow	-7374000	Operating Cash Flow: -5891000 Open source Capital Expenditure: 1483000 Open source
20072007-12-31	Free cash flow	-14618000	Operating Cash Flow: -14252000 Open source Capital Expenditure: 366000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2003-12-31	Liabilities / assets	Not reported	No source recorded
2004-12-31	Liabilities / assets	Not reported	Total Assets: 28332000 Open source
2005-12-31	Liabilities / assets	Not reported	Total Assets: 33112000 Open source
2006-12-31	Liabilities / assets	Not reported	Total Assets: 48464000 Open source
2007-12-31	Liabilities / assets	Not reported	Total Assets: 51056000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.72× 2007

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2003-12-31	Current assets / current liabilities	Not reported	No source recorded
20042004-12-31	Current assets / current liabilities	0.61×	Current Assets: 13660000 Open source Current Liabilities: 22294000 Open source
20052005-12-31	Current assets / current liabilities	1.03×	Current Assets: 19822000 Open source Current Liabilities: 19204000 Open source
20062006-12-31	Current assets / current liabilities	1.79×	Current Assets: 39025000 Open source Current Liabilities: 21762000 Open source
20072007-12-31	Current assets / current liabilities	1.72×	Current Assets: 42883000 Open source Current Liabilities: 24991000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2003 2003-01-01 – 2003-12-31	−USD 18.76 million Exact value Exact value: -18761000 USD 2003-01-01 – 2003-12-31: -18761000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SGX PHARMACEUTICALS, INC. · 2003-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Net Income: -18761000 USD Concept: fundies:NetIncome Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3ANetIncome&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18761000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-06-000299.txt#23161 The citation records this snapshot. The page link may show a newer release later.	−USD 6.31 million Exact value Exact value: -6312000 USD 2003-01-01 – 2003-12-31: -6312000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SGX PHARMACEUTICALS, INC. · 2003-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Operating Cash Flow: -6312000 USD Concept: fundies:OperatingCashFlow Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3AOperatingCashFlow&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6312000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-06-000299.txt#23916 The citation records this snapshot. The page link may show a newer release later.	USD 1.31 million Exact value Exact value: 1313000 USD 2003-01-01 – 2003-12-31: 1313000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SGX PHARMACEUTICALS, INC. · 2003-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Capital Expenditure: 1313000 USD Concept: fundies:CapitalExpenditure Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3ACapitalExpenditure&period=2003-12-31&surface=latest&period_type=duration&start=2003-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1313000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-06-000299.txt#24005 The citation records this snapshot. The page link may show a newer release later.	−USD 7.63 million Calculation and evidence -6312000 − 1313000 USD Exact free cash flow: -7625000 USD 2003-01-01 – 2003-12-31: -6312000 USD · Inspect Operating Cash Flow · Source 2003-01-01 – 2003-12-31: 1313000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SGX PHARMACEUTICALS, INC. · 2003-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Free cash flow: -7625000 USD Concept: free-cash-flow Period: 2003-01-01 to 2003-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6312000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-06-000299.txt#23916 Input fundies:CapitalExpenditure: 1313000 USD (2003-01-01 to 2003-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-06-000299.txt#24005 The citation records this snapshot. The page link may show a newer release later.
2004 2004-01-01 – 2004-12-31	−USD 18.75 million Exact value Exact value: -18752000 USD 2004-01-01 – 2004-12-31: -18752000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SGX PHARMACEUTICALS, INC. · 2004-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Net Income: -18752000 USD Concept: fundies:NetIncome Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3ANetIncome&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18752000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-07-000246.txt#21542 The citation records this snapshot. The page link may show a newer release later.	−USD 10.98 million Exact value Exact value: -10984000 USD 2004-01-01 – 2004-12-31: -10984000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SGX PHARMACEUTICALS, INC. · 2004-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Operating Cash Flow: -10984000 USD Concept: fundies:OperatingCashFlow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3AOperatingCashFlow&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10984000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-07-000246.txt#22386 The citation records this snapshot. The page link may show a newer release later.	USD 1.18 million Exact value Exact value: 1175000 USD 2004-01-01 – 2004-12-31: 1175000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SGX PHARMACEUTICALS, INC. · 2004-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Capital Expenditure: 1175000 USD Concept: fundies:CapitalExpenditure Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3ACapitalExpenditure&period=2004-12-31&surface=latest&period_type=duration&start=2004-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1175000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-07-000246.txt#22519 The citation records this snapshot. The page link may show a newer release later.	−USD 12.16 million Calculation and evidence -10984000 − 1175000 USD Exact free cash flow: -12159000 USD 2004-01-01 – 2004-12-31: -10984000 USD · Inspect Operating Cash Flow · Source 2004-01-01 – 2004-12-31: 1175000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SGX PHARMACEUTICALS, INC. · 2004-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Free cash flow: -12159000 USD Concept: free-cash-flow Period: 2004-01-01 to 2004-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10984000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-07-000246.txt#22386 Input fundies:CapitalExpenditure: 1175000 USD (2004-01-01 to 2004-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-07-000246.txt#22519 The citation records this snapshot. The page link may show a newer release later.
2005 2005-01-01 – 2005-12-31	−USD 29.39 million Exact value Exact value: -29391000 USD 2005-01-01 – 2005-12-31: -29391000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SGX PHARMACEUTICALS, INC. · 2005-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Net Income: -29391000 USD Concept: fundies:NetIncome Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3ANetIncome&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29391000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21038 The citation records this snapshot. The page link may show a newer release later.	−USD 11.84 million Exact value Exact value: -11842000 USD 2005-01-01 – 2005-12-31: -11842000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SGX PHARMACEUTICALS, INC. · 2005-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Operating Cash Flow: -11842000 USD Concept: fundies:OperatingCashFlow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3AOperatingCashFlow&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11842000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21809 The citation records this snapshot. The page link may show a newer release later.	USD 1.3 million Exact value Exact value: 1303000 USD 2005-01-01 – 2005-12-31: 1303000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SGX PHARMACEUTICALS, INC. · 2005-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Capital Expenditure: 1303000 USD Concept: fundies:CapitalExpenditure Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3ACapitalExpenditure&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1303000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21981 The citation records this snapshot. The page link may show a newer release later.	−USD 13.15 million Calculation and evidence -11842000 − 1303000 USD Exact free cash flow: -13145000 USD 2005-01-01 – 2005-12-31: -11842000 USD · Inspect Operating Cash Flow · Source 2005-01-01 – 2005-12-31: 1303000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SGX PHARMACEUTICALS, INC. · 2005-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Free cash flow: -13145000 USD Concept: free-cash-flow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11842000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21809 Input fundies:CapitalExpenditure: 1303000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21981 The citation records this snapshot. The page link may show a newer release later.
2006 2006-01-01 – 2006-12-31	−USD 28.05 million Exact value Exact value: -28052000 USD 2006-01-01 – 2006-12-31: -28052000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SGX PHARMACEUTICALS, INC. · 2006-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Net Income: -28052000 USD Concept: fundies:NetIncome Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3ANetIncome&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28052000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21038 The citation records this snapshot. The page link may show a newer release later.	−USD 5.89 million Exact value Exact value: -5891000 USD 2006-01-01 – 2006-12-31: -5891000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SGX PHARMACEUTICALS, INC. · 2006-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Operating Cash Flow: -5891000 USD Concept: fundies:OperatingCashFlow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3AOperatingCashFlow&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5891000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21809 The citation records this snapshot. The page link may show a newer release later.	USD 1.48 million Exact value Exact value: 1483000 USD 2006-01-01 – 2006-12-31: 1483000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SGX PHARMACEUTICALS, INC. · 2006-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Capital Expenditure: 1483000 USD Concept: fundies:CapitalExpenditure Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3ACapitalExpenditure&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1483000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21981 The citation records this snapshot. The page link may show a newer release later.	−USD 7.37 million Calculation and evidence -5891000 − 1483000 USD Exact free cash flow: -7374000 USD 2006-01-01 – 2006-12-31: -5891000 USD · Inspect Operating Cash Flow · Source 2006-01-01 – 2006-12-31: 1483000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SGX PHARMACEUTICALS, INC. · 2006-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Free cash flow: -7374000 USD Concept: free-cash-flow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5891000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21809 Input fundies:CapitalExpenditure: 1483000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21981 The citation records this snapshot. The page link may show a newer release later.
2007 2007-01-01 – 2007-12-31	−USD 16.01 million Exact value Exact value: -16007000 USD 2007-01-01 – 2007-12-31: -16007000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SGX PHARMACEUTICALS, INC. · 2007-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Net Income: -16007000 USD Concept: fundies:NetIncome Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3ANetIncome&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16007000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21038 The citation records this snapshot. The page link may show a newer release later.	−USD 14.25 million Exact value Exact value: -14252000 USD 2007-01-01 – 2007-12-31: -14252000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SGX PHARMACEUTICALS, INC. · 2007-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Operating Cash Flow: -14252000 USD Concept: fundies:OperatingCashFlow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3AOperatingCashFlow&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14252000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21809 The citation records this snapshot. The page link may show a newer release later.	USD 366,000 Exact value Exact value: 366000 USD 2007-01-01 – 2007-12-31: 366000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SGX PHARMACEUTICALS, INC. · 2007-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Capital Expenditure: 366000 USD Concept: fundies:CapitalExpenditure Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603/explain?concept=fundies%3ACapitalExpenditure&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 366000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21981 The citation records this snapshot. The page link may show a newer release later.	−USD 14.62 million Calculation and evidence -14252000 − 366000 USD Exact free cash flow: -14618000 USD 2007-01-01 – 2007-12-31: -14252000 USD · Inspect Operating Cash Flow · Source 2007-01-01 – 2007-12-31: 366000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SGX PHARMACEUTICALS, INC. · 2007-12-31 SGX PHARMACEUTICALS, INC. (edgar:1125603) Free cash flow: -14618000 USD Concept: free-cash-flow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1125603?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14252000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21809 Input fundies:CapitalExpenditure: 366000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1125603/0000936392-08-000227.txt#21981 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

11 filings · 0 latest values · 0 originally reported values

Dataset published 2026-11-06. Source filing dates and reporting periods are shown separately.

Identifiers: 0001125603, 1125603, edgar:1125603

Also known as STRUCTURAL GENOMIX INC

SGX PHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2007 2007-01-01 – 2007-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation